Tempus AI Shares Rise 4.18% as Q3 Earnings Beat Forecasts and Revenue Guidance Increases
Tempus AI (TEM) shares rose 4.18% after reporting Q3 2026 earnings of $0.07 per share, beating estimates. Revenue grew 23% YoY to $411.5M, with diagnostics up 20% and data services up 33%. The company raised full-year revenue guidance to $1.60B-$1.605B, up 25% YoY, and maintained adjusted EBITDA forecast of $65M.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise provide a clear catalyst for short‑term buying, while the expanded pharma partnerships may support longer‑term growth.
Market read
The report delivers fresh, material earnings data and guidance that can move the stock immediately.
What to watch
Potential volatility from upcoming regulatory scrutiny of data licensing agreements.
Background
Tempus AI is a Nasdaq‑listed healthcare‑technology company focusing on oncology diagnostics and data services.
Ticker impact
Tempus AI reported Q3 earnings beat and raised full-year revenue guidance, driving a 4.18% pre‑market price rise.
likely upward pressure as the market prices in the earnings beat and higher revenue outlook
Adjusted EPS of $0.07 beat consensus $0.01 and revenue guidance lifted to $1.60‑$1.605B, both material new data.
Market effects
Strengthens outlook for healthcare‑technology and oncology diagnostics sector.
Positive for US biotech and data‑services stocks.
May boost investor sentiment toward AI‑enabled health‑tech firms worldwide.
Counterpoint
If guidance is overly optimistic, the stock could face a pull‑back once detailed unit economics are scrutinized.
Key entities
- CompanyTempus AI, Inc.
Healthcare‑technology firm reporting earnings.
- PartnerBristol Myers Squibb
Pharma partner in data‑licensing agreement.
- PartnerMerck
Pharma partner in data‑licensing agreement.
- PartnerModerna
Pharma partner in data‑licensing agreement.
